The US Food and Drug Administration on Thursday authorized the Pfizer/BioNTech Covid-19 vaccine for use as a booster in people ages 16 and 17, and the US Centers for Disease Control and Prevention recommended it for this age group.
It’s the first Covid-19 vaccine booster authorized for 16- and 17-year-olds in the United States.
Just as with adults, 16- and 17-year-olds are eligible to receive a booster dose six months after their second dose of the Pfizer/BioNTech vaccine. About 2.6 million US teens in this age group would be eligible for boosters already – a small addition to the 141 million adults already eligible for boosters.
“The Pfizer-BioNTech COVID-19 Vaccine has been available to individuals 16 years of age and older for nearly a y